GLP-2 and Bone Resorption. A double-blind, randomized, placebo-controlled, dose ranging, safety, tolerability and pharmacokinetic/dynamic efficacy study with multiple subcutaneous injections of GLP-2 in postmenopausal female volunteers. 120 Days of Treatment

Trial Profile

GLP-2 and Bone Resorption. A double-blind, randomized, placebo-controlled, dose ranging, safety, tolerability and pharmacokinetic/dynamic efficacy study with multiple subcutaneous injections of GLP-2 in postmenopausal female volunteers. 120 Days of Treatment

Recruiting
Phase of Trial: Phase II

Latest Information Update: 28 Aug 2014

At a glance

  • Drugs Glucagon-like peptide-2 (Primary)
  • Indications Bone resorption; Postmenopausal osteoporosis
  • Focus Adverse reactions; Biomarker; Therapeutic Use
  • Acronyms GBR
  • Sponsors SANOS BIOSCIENCE
  • Most Recent Events

    • 25 May 2011 Trial identifier identified and integrated (EudraCT2005-003076-37).
    • 05 Nov 2010 New trial record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top